Mediso, a manufacturer of nuclear medicine imaging equipment based in Hungary, has announced the completion of the initial phase of a technology transfer arrangement with Superconducting Systems (SSI), a subsidiary of IMRIS.
According to Mediso, this development signifies a key step in its effort towards vertical integration and innovation in MRI system development.
For over 10 years, Mediso is said to have employed SSI’s cryogen-free superconducting magnets, leading to the successful launch of the nanoScan 3T and 7T MRI systems. These systems are claimed to have eliminated the necessity for liquid helium, thereby setting a new benchmark in preclinical MRI.
With the first phase of the transfer finalised, Mediso is enhancing its European magnet manufacturing capabilities, aiming for full-scale production by year-end. This includes integrating Mediso’s quality management systems into its production process.
Mediso preclinical product development director Gergo Bagamery said: “This is the last piece of the puzzle for Mediso for a complete vertical integration of its MRI products and the way forward in developing new MRI systems, up to 9.4T.
“Owning the magnet technology allows us to create novel designs across a range of field strengths and bore sizes with unmatched flexibility.”
The transferred technology allows Mediso to access SSI’s intellectual property and patented technologies, enabling them to produce conduction-cooled superconducting magnets optimised for bore sizes up to 9.4T.
SSI CTO Shahin Pourrahimi said: “Our collaboration with Mediso over the past decade has demonstrated the strength of our cryogen-free magnet technology in imaging.
“We are excited to see this technology further evolve with this technology transfer.”
In October 2024, Mediso unveiled its AnyScan TRIO SPECT/CT, TheraMAX scanner. This device is tailored for theranostic imaging needs in clinics and incorporates detectors and collimators suited for Targeted Radionuclide Therapies with various radioisotopes.
